Blood Tests While Taking Atorvastatin
Atorvastatin is one of the most prescribed medicines in the UK, used to lower cholesterol and reduce the risk of heart attack and stroke. Starting a statin comes with a short series of blood tests, and many active people are surprised when a result comes back flagged after a hard training week. Our editorial team explains which tests are done, when, and how to avoid misleading results.
Why monitoring is needed
Atorvastatin works by blocking HMG-CoA reductase, a key liver enzyme in cholesterol production. The liver responds by pulling more LDL cholesterol out of the bloodstream. Large trials analysed by the Cholesterol Treatment Trialists' Collaboration show that each 1 mmol/L reduction in LDL cholesterol lowers major cardiovascular events by roughly a fifth.
Blood tests have three purposes: to confirm the drug is working, to pick up rare but important side effects affecting the liver or muscles, and to identify other conditions that can raise cholesterol, such as an underactive thyroid or kidney disease.
In the UK, monitoring follows NICE guideline NG238 on cardiovascular risk assessment and lipid modification, published in 2023. Local practice may differ slightly, and your GP or pharmacist will tell you exactly which tests your surgery uses.
Atorvastatin is a prescription-only medicine. The licensed dose range is 10–80 mg once daily; the dose you take is decided by your prescriber according to your risk and response, and should not be changed without discussing it with them.
Tests before you start
Before atorvastatin is prescribed, a baseline set of tests is usually arranged. This creates a reference point and checks for secondary causes of high cholesterol.
- Full lipid profile: total cholesterol, HDL, non-HDL cholesterol and triglycerides; LDL is often calculated.
- Liver function tests: particularly ALT, an enzyme that rises when liver cells are irritated.
- HbA1c: a measure of average blood glucose, because diabetes affects cardiovascular risk and statins slightly increase the chance of developing it.
- Kidney function: creatinine and eGFR, plus a urine test for protein in some cases.
- Thyroid function (TSH): if there are symptoms of hypothyroidism, which can raise cholesterol and increase muscle side effects.
- Creatine kinase (CK): only if you have unexplained muscle pain or other risk factors before starting.
Routine CK measurement in people without symptoms is not recommended, because the enzyme fluctuates widely, especially in people who exercise.
Monitoring during treatment
After starting atorvastatin, the key follow-up checks are a repeat lipid profile and liver function test, usually around three months in. NICE suggests aiming for a reduction in non-HDL cholesterol of more than 40 per cent from baseline for primary prevention; for people with established cardiovascular disease, lipid targets are now more ambitious.
ALT is commonly rechecked at 12 months, then only if clinically indicated. A rise in ALT to less than three times the upper limit of normal is common and usually not a reason to stop the statin. Persistently higher levels require review.
Lipids are usually reviewed annually as part of a medication check, alongside a discussion about adherence, side effects, diet and physical activity. If targets are not met, the prescriber may adjust the dose or consider adding another medicine such as ezetimibe.
| Test | When | What a concerning result looks like |
|---|---|---|
| Lipid profile | Baseline, about 3 months, then annually | Non-HDL reduction well under target |
| ALT | Baseline, 3 months, 12 months | More than three times the upper limit of normal |
| CK | Only with muscle symptoms or risk factors | More than five times the upper limit with symptoms |
| HbA1c | Baseline; repeat per diabetes risk | Rising into the pre-diabetes or diabetes range |
Exercise and misleading results
Hard physical training can produce blood results that look alarming on paper. Heavy resistance work, long runs, eccentric exercise such as downhill running and contact sports can raise CK many times above the reference range for several days.
ALT and AST are not only liver enzymes; they are also present in muscle. After an intense session, both can rise, mimicking liver irritation. This can lead to unnecessary concern or even inappropriate withdrawal of a statin.
A practical approach is to avoid strenuous or unfamiliar exercise for around 48–72 hours before blood tests, keep hydration normal, and tell the clinician about your training. If a CK result is raised, the test can be repeated after a period of rest.
The STOMP study by Parker and colleagues found that high-dose atorvastatin slightly increased CK compared with placebo but did not reduce muscle strength or exercise capacity on average. Some individuals do develop muscle symptoms, so persistent pain, weakness or dark urine should always be reported promptly.
Side effects worth knowing
An individual participant meta-analysis of large randomised trials, published in The Lancet in 2022, found that statins caused only a small excess of muscle symptoms, and that over 90 per cent of muscle complaints reported by people on statins were not actually due to the drug.
Serious muscle damage (rhabdomyolysis) is rare but more likely at high doses, in older people, with hypothyroidism or kidney disease, and with interacting medicines such as certain antibiotics, antifungals or ciclosporin. Large amounts of grapefruit juice can also raise atorvastatin levels.
Statins modestly increase the risk of type 2 diabetes, mainly in people already near the threshold. Sattar and colleagues found that this risk is far outweighed by cardiovascular benefit in most patients, which is why HbA1c is checked rather than avoiding statins.
Supplements such as red yeast rice contain a statin-like compound and should not be combined with atorvastatin. Tell your pharmacist about any sports supplements you use, particularly those claiming to affect liver or muscle.
Editorial conclusions
Blood tests on atorvastatin are straightforward: a baseline panel, a lipid and liver check after about three months, a further liver test at a year and annual lipid reviews thereafter.
CK is checked only when there are symptoms or risk factors, and mildly raised liver enzymes are usually not a reason to stop treatment.
For active people, avoiding strenuous exercise for a couple of days before testing and telling the clinician about training helps prevent misleading results.
Readers may also be interested in our editorial guides on preparing for an HDL and LDL test, on creatine kinase in athletes and on how exercise affects liver enzymes.
References
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG238. London: NICE; 2023.
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–845.
- Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81.
- Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103.
- Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
